BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 536 filers reported holding BIO-TECHNE CORP in Q1 2023. The put-call ratio across all filers is 0.40 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,937 | -16.3% | 72,534 | +0.4% | 0.03% | -12.9% |
| Q2 2023 | $5,897 | +13.2% | 72,246 | +2.9% | 0.03% | +3.3% |
| Q1 2023 | $5,209 | -9.9% | 70,216 | +0.6% | 0.03% | -14.3% |
| Q4 2022 | $5,783 | -99.9% | 69,776 | +305.7% | 0.04% | +9.4% |
| Q3 2022 | $4,885,000 | -17.1% | 17,199 | +1.2% | 0.03% | -13.5% |
| Q2 2022 | $5,893,000 | -9.0% | 16,999 | +13.7% | 0.04% | +2.8% |
| Q1 2022 | $6,475,000 | -15.0% | 14,953 | +1.5% | 0.04% | -10.0% |
| Q4 2021 | $7,618,000 | +8.3% | 14,725 | +1.4% | 0.04% | -2.4% |
| Q3 2021 | $7,034,000 | +11.2% | 14,515 | +3.3% | 0.04% | +10.8% |
| Q2 2021 | $6,324,000 | +12.7% | 14,046 | -4.4% | 0.04% | +5.7% |
| Q1 2021 | $5,609,000 | +21.3% | 14,686 | +0.8% | 0.04% | +12.9% |
| Q4 2020 | $4,625,000 | +28.6% | 14,566 | +0.3% | 0.03% | +14.8% |
| Q3 2020 | $3,596,000 | -6.3% | 14,516 | -0.1% | 0.03% | -15.6% |
| Q2 2020 | $3,839,000 | +29.2% | 14,536 | -7.2% | 0.03% | +23.1% |
| Q1 2020 | $2,972,000 | +49.6% | 15,672 | +73.2% | 0.03% | +62.5% |
| Q4 2019 | $1,986,000 | +13.1% | 9,046 | +0.8% | 0.02% | 0.0% |
| Q3 2019 | $1,756,000 | -44.1% | 8,976 | -40.4% | 0.02% | -15.8% |
| Q2 2019 | $3,139,000 | +2.8% | 15,056 | -2.1% | 0.02% | -5.0% |
| Q1 2019 | $3,054,000 | +38.6% | 15,382 | +1.0% | 0.02% | +25.0% |
| Q4 2018 | $2,204,000 | -25.2% | 15,230 | +5.5% | 0.02% | -15.8% |
| Q3 2018 | $2,947,000 | +137.3% | 14,438 | +71.9% | 0.02% | +46.2% |
| Q2 2018 | $1,242,000 | +139.3% | 8,398 | +144.5% | 0.01% | -7.1% |
| Q1 2018 | $519,000 | – | 3,435 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 46,500 | $16,119,000 | 8.75% |
| Montanaro Asset Management Ltd | 93,950 | $32,567,000 | 4.90% |
| Jackson Square Partners, LLC | 556,157 | $192,786,000 | 4.50% |
| STONE RUN CAPITAL, LLC | 22,405 | $7,767,000 | 3.91% |
| Ownership Capital B.V. | 655,654 | $227,276,000 | 3.90% |
| Brown Capital Management | 839,587 | $291,034,000 | 3.90% |
| Sandhill Capital Partners LLC | 97,382 | $33,757,000 | 3.61% |
| DF DENT & CO INC | 684,026 | $237,111,000 | 3.34% |
| Westwind Capital | 27,946 | $9,687,000 | 3.17% |
| MAIRS & POWER INC | 655,930 | $227,371,000 | 2.72% |